Exact Sciences, Mayo Clinic study 'shows promise' for lung cancer test
A study from Exact Sciences and Mayo Clinic released today by the American Association of Cancer Research shows promise for the development of a blood-based lung cancer test. Researchers conducted a multi-round study of nearly 400 patients, which demonstrated high accuracy for detecting lung cancer at all stages. "These results reveal an opportunity to detect lung cancer from a simple blood draw," said Kevin Conroy, chairman and CEO of Exact Sciences. "Our collaboration with Mayo Clinic is efficiently identifying biomarkers for additional cancer applications on the same technology platform as Cologuard." AACR released an abstract of the study today, ahead of the presentation of the results on April 2, 2017, during the AACR 2017 annual meeting. The findings from the study of 398 patients demonstrate that biomarkers in plasma achieved high accuracy for all types and stages of lung cancer. Using two independent regression modeling approaches, a panel of four novel methylated DNA markers demonstrated a sensitivity of 91%-96% at a specificity of 90%-94%.